Connect your AI

Opus Genetics IRD Interest Paid, Excluding Capitalized Interest, Operating Activity

Interest Paid, Excluding Capitalized Interest, Operating Activity at other companies

Sarepta Therapeutics, Inc.SRPT

——

Other financials

Income statement

Revenue$2.2M-50.6%

Operating income-$14.4M-44.7%

Net income-$65.5M-700%

EPS (diluted)-$0.75-213%

Balance sheet

Cash & equivalents$60.0M+43.5%

Total debt$1.2M—

Total equity-$45.8M-1,004%

Total assets$66.8M+38.7%

Cash flow

Operating cash flow-$12.7M-41.5%

Valuation

Market cap$307.14M+442%

Enterprise value$248.38M—

P/S25.6×+21.5×

Profitability

Operating margin-359.1%-68.9pp

Net margin-892.4%-12,322pp

Returns & leverage

Return on equity-449.4%-2,573pp

Debt / equity0.1×—

Current ratio7.1×+5.2×

Where this comes from

Reported directly by Opus Genetics in its filing.

Tagged under the XBRL concept us-gaap:InterestPaidNet.

The official record: Opus Genetics’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Opus Genetics's interest paid, excluding capitalized interest, operating activity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Opus Genetics's interest paid, excluding capitalized interest, operating activity?: Opus Genetics (IRD) reported interest paid, excluding capitalized interest, operating activity of $0 in Q1 2026.
What is the long-term trend for Opus Genetics's interest paid, excluding capitalized interest, operating activity?: Over 3 years (2021 to 2025), Opus Genetics's interest paid, excluding capitalized interest, operating activity has grown at a -100.0% compound annual growth rate (CAGR), from $2K to $0.